NCT06052683 A Trial Evaluating Toxicity of SBRT and LDRB in Localized Prostate Cancer.
| NCT ID | NCT06052683 |
| Status | Recruiting |
| Phase | — |
| Sponsor | CHU de Quebec-Universite Laval |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 208 participants |
| Start Date | 2019-09-30 |
| Primary Completion | 2028-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 208 participants in total. It began in 2019-09-30 with a primary completion date of 2028-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare SBRT (Stereotactic Body RadioTherapy) to LDRB (Low-Dose Rate Brachytherapy with Iodine-125 seed implant) in patients with low and favourable intermediate-risk prostate cancer. The two main questions it aims to answer are : 1. Does SBRT (Stereotactic Body RadioTherapy) for low and intermediate risk prostate cancer patients will result in less genito-urinary (GU) and gastro-intestinal (GI) toxicities than LDRB (Low-Dose Rate Brachytherapy)? 2. Does prostate cancer patients treated by SBRT have a better quality of life than patients treated by LDRB No randomized trial has yet compared LDRB to SBRT head to head.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate diagnosed within the last 8 months. Patients on active surveillance with evidence of disease progression are eligible to the protocol as long as they meet the eligibility criteria and have a recent prostate biopsy (within 8 months). * Low-risk and favourable intermediate-risk prostate cancer patients are eligible according to the following definitions: Low-risk disease defined as: Clinical stage T1-T2a and Gleason 6 and PSA ≤ 10 ng/mL Favourable intermediate-risk cancer defined by a single NCCN intermediate risk factor: \[NCCN : National Comprehensive Cancer Network\] 1. Clinical stage T2b 2. PSA \> 10 but ≤ 20 ng/mL 3. Gleason 7 (3+4) Lymph node evaluation by either computed tomography (CT) or magnetic resonance imaging (MRI) is optional and is left at the discretion of the treating physician. * Age ≥ 18 years * Eastern Cooperative Oncology Group performance status 0-1 * Patient considered medically fit for LDR brachytherapy * Prostate volume ≤ 60 cc, measured by Trans-Rectal UltraSound (TRUS), CT or MRI, within the last 6 months. * International Prostate Symptom Score (IPSS) ≤ 20 (alpha blockers allowed) * No alpha reductase inhibitors use within two weeks of randomization * No hormonal therapy is accepted * Patients must provide a study-specified informed consent form prior to study entry. * Patients must be willing and able to complete the EPIC-26, IPSS and SHIM questionnaires. \[EPIC-26: Expanded Prostate Cancer Index Composite score ; SHIM: Sexual Health Inventory for Men questionnaire\]. Exclusion Criteria: * Clinical or radiological evidence of metastatic disease or nodal involvement. * Clinical stage ≥ T2b. * Gleason score ≥ 4 + 3. * Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, or other solid tumors curatively treated with no evidence of disease for ≥ 3 years. * Prior radical surgery for carcinoma of the prostate, or prior TURP (Trans-Urethral Resection of the Prostate). * Prior pelvic radiotherapy or prior radiotherapy that would result in overlap of radiation fields. * Prior chemotherapy for prostate cancer, or prior chemotherapy within the last 3 years. * Prior cryosurgery of the prostate. * Prior or current bleeding diathesis making fiducial placement or brachytherapy procedure unsafe. * Previous androgen deprivation therapy within 6 months of the registration. * Bilateral hip prostheses * Any severe active comorbidity, laboratory abnormality, psychiatric illnesses, active or uncontrolled infections, serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator's decision). Such examples includes active inflammatory bowel disease, significant urinary symptoms,
Contact & Investigator
Isabelle Thibault, MD, FRCPC
STUDY CHAIR
CHU de Québec-Université Laval
Frequently Asked Questions
Who can join the NCT06052683 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06052683 currently recruiting?
Yes, NCT06052683 is actively recruiting participants. Contact the research team at isabelle.thibault.med@ssss.gouv.qc.ca for enrollment information.
Where is the NCT06052683 trial being conducted?
This trial is being conducted at Québec, Canada.
Who is sponsoring the NCT06052683 clinical trial?
NCT06052683 is sponsored by CHU de Quebec-Universite Laval. The principal investigator is Isabelle Thibault, MD, FRCPC at CHU de Québec-Université Laval. The trial plans to enroll 208 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.